Comparison of efficacy, safety and brain derived neurotrophic factor (BDNF) levels in patients of major depressive disorder, treated with fluoxetine and desvenlafaxine

Asian Journal of Psychiatry

Volumn 18, Issue , 2015, Pages 37-41

  Ghosh, R ^a   Gupta, R ^a   Bhatia, M S ^a   Tripathi, A K ^a   Gupta, L K ^b  

^a UNIVERSITY COLLEGE OF MEDICAL SCIENCES   (India)

^b LADY HARDINGE MEDICAL COLLEGE   (India)

Author keywords

BDNF; Depression; Desvenlafaxine; Fluoxetine; MDD; Open label

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; DESVENLAFAXINE; FLUOXETINE; ANTIDEPRESSANT AGENT;

ADULT; ANOREXIA; ARTICLE; ASTHENIA; BLURRED VISION; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DSM-IV; DYSURIA; FEMALE; FOLLOW UP; HAMILTON DEPRESSION RATING SCALE; HEADACHE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; NAUSEA; OBSERVATIONAL STUDY; OPEN STUDY; OUTPATIENT; PRESCRIPTION; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SEXUAL DYSFUNCTION; SOMNOLENCE; TACHYCARDIA; TASTE DISORDER; TREMOR; XEROSTOMIA; DEPRESSIVE DISORDER, MAJOR; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG MONITORING; METABOLISM; MIDDLE AGED; PROCEDURES; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; TREATMENT OUTCOME;

ADULT; ANTIDEPRESSIVE AGENTS; BRAIN-DERIVED NEUROTROPHIC FACTOR; DEPRESSIVE DISORDER, MAJOR; DESVENLAFAXINE SUCCINATE; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG MONITORING; FEMALE; FLUOXETINE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PSYCHIATRIC STATUS RATING SCALES; TREATMENT OUTCOME;

EID: 84955397083     PISSN: 18762018     EISSN: 18762026     Source Type: Journal    
DOI: 10.1016/j.ajp.2015.10.006     Document Type: Article

References (43)

1. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 2000, American Psychiatric Association, Washington, DC, (Text Revision). fourth ed.
2. Aydemir O., Deveci A., Taneli F. The effect of chronic antidepressant treatment on serum brain-derived neurotrophic factor levels in depressed patients: a preliminary study. Prog. Neuropsychopharmacol. Biol. Psychiatry 2005, 29:61-65.
3. Basterzi A.D., Yazici K., Aslan E., Delialioglu N., Tasdelen B., Acar S.T., Yazici A. Effects of fluoxetine and venlafaxine on serum brain-derived neurotrophic factor levels in depressed patients. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2009, 33:281-285.
4. Bocchio-Chiavetto L., Bagnardi V., Zanardini R., Molteni R., Nielsen M.G., Placentino A., Giovannini C., Rillosi L., Ventriglia M., Riva M.A., Gennarelli M. Serum and plasma BDNF levels in major depression: a replication study and meta-analyses. World J. Biol. Psychiatry 2010, 11:763-773.
5. Boyer P., Montgomery S., Lepola U., Germain J.M., Brisard C., Ganguly R., Padmanabhan S.K., Tourian K.A. Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100mg/day for major depressive disorder in a placebo-controlled trial. Int. Clin. Psychopharmacol. 2008, 23:243-253.
6. Brunoni A.R., Lopes M., Fregni F. A systematic review and meta-analysis of clinical studies on major depression and BDNF levels: implications for the role of neuroplasticity in depression. Int. J. Neuropsychopharmacol. 2008, 11:1169-1180.
7. DeMartinis N.A., Yeung P.P., Entsuah R., Manley A.L. A double-blind, placebo-controlled study of the efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder. J. Clin. Psychiatry 2007, 68:677-688.
8. Duman R.S., Heninger G.R., Nestler E.J. A molecular and cellular theory of depression. Arch. Gen. Psychiatry 1997, 54:597-606.
9. Duman R.S., Monteggia L.M. A neurotrophic model for stress-related mood disorders. Biol. Psychiatry 2006, 59:1116-1127.
10. Dunlop B.W., Reddy S., Yang L., Lubaczewski S., Focht K., Guico-Pabia C.J. Symptomatic and functional improvement in employed depressed patients: a double-blind clinical trial of desvenlafaxine versus placebo. J. Clin. Psychopharmacol. 2011, 31:569-576.
11. Egan M.F., Kojima M., Callicott J.H., Goldberg T.E., Kolachana B.S., Bertolino A., Zaitsev E., Gold B., Goldman D., Dean M., Lu B., Weinberger D.R. The BDNF val66met polymorphism affects activity dependent secretion of BDNF and human memory and hippocampal function. Cell 2003, 112:257-269.
12. Fujimura H., Altar C.A., Chen R., Nakamura T., Nakahashi T., Kambayashi J., Sun B., Tandon N.N. Brain-derived neurotrophic factor isstored in human platelets and released by agonist stimulation. Thromb. Haemost. 2002, 87:728-734.
13. Gonul A.S., Akdeniz F., Taneli F., Donat O., Eker C., Vahip S. Effect of treatment on serum brain-derived neurotrophic factor levels in depressed patients. Eur. Arch. Psychiatry Clin. Neurosci. 2005, 255:381-386.
14. Groves J.O. Is it time to reassess the BDNF hypothesis of depression?. Mol. Psychiatry 2007, 12:1079-1088.
15. Hamilton M. A rating scale for depression. J. Neurol. Neurosurg. Psychiatry 1960, 23:56-62.
16. Hashimoto K., Shimizu E., Iyo M. Critical role of brain-derived neurotrophic factor in mood disorders. Brain Res. Rev. 2004, 45:104-114.
17. Herbert E., Covington V., Vialou V., Eric J. From synapse to nucleus: novel targets for treating depression. Neuropharmacology 2010, 58:683-693.
18. Hoshaw B.A., Malberg J.E., Lucki I. Central administration of IGF-I and BDNF leads to long-lastingantidepressant-like effects. Brain Res. 2005, 1037:204-208.
19. Huang T.L., Lee C.T., Liu Y.L. Serum brain-derived neurotrophic factor levels in patients with major depression: effects of antidepressants. J. Psychiatr. Res. 2008, 42:521-525.
20. Iwata N., Tourian K.A., Hwang E., Mele L., Vialet C. Efficacy and safety of desvenlafaxine 25 and 50mg/day in a randomized, placebo-controlled study of depressed outpatients. J. Psychiatr. Pract. 2013, 19:5-14.
21. Karege F., Bondolfi G., Gervasoni N., Schwald M., Aubry J.M., Bertschy G. Low brain-derived neurotrophic factor (BDNF) levels in serum of depressed patients probably results from lowered platelet BDNF release unrelated to platelet reactivity. Biol. Psychiatry 2005, 57:1068-1072.
22. Lewin G.R., Barde Y.A. Physiology of the neurotrophins. Annu. Rev. Neurosci. 1996, 19:289-317.
23. Liebowitz M.R., Manley A.L., Padmanabhan S.K., Ganguly R., Tummala R., Tourian K.A. Efficacy, safety, and tolerability of desvenlafaxine 50mg/day and 100mg/day in outpatients with major depressive disorder. Curr. Med. Res. Opin. 2008, 24:1877-1890.
24. Liebowitz M.R., Tourian K.A., Hwang E., Mele L. A double-blind, randomized, placebo-controlled study assessing the efficacy and tolerability of desvenlafaxine 10 and 50mg/day in adult outpatients with major depressive disorder. BMC Psychiatry 2013, 13:94. Study 3362 Investigators.
25. Lommatzsch M., Zingler D., Schuhbaeck K., Schloetcke K., Zingler C., Schuff-Werner P., Virchow J.C. The impact of age, weight and gender on BDNF levels in human platelets and plasma. Neurobiol. Aging 2005, 26:115-123.
26. Matrisciano F., Bonaccorso S., Ricciardi A., Scaccianoce S., Panaccione I., Wang L., Ruberto A., Tatarelli R., Nicoletti F., Girardi P., Shelton R.C. Changes in BDNF serum levels in patients with major depression disorder (MDD) after 6 months treatment with sertraline, ecitalopram, or venlafaxine. J. Psychiatr. Res. 2009, 43:247-254.
27. Nibuya M., Morinobu S., Duman R.S. Regulation of BDNF and TrkB mRNA in rat brainby chronic electroconvulsive seizure and antidepressant drug treatments. J. Neurosci. 1995, 15:7539-7547.
28. Nibuya M., Nestler E.J., Duman R.S. Chronic antidepressant administration increases the expression of camp response element binding protein (CREB) in rat hippocampus. J. Neurosci. 1996, 16:2365-2372.
29. Ninan P.T., Shelton R.C., Bao W., Guico-Pabia C.J. BDNF, interleukin-6, and salivary cortisol levels in depressed patients treated with desvenlafaxine. Prog. Neuropsychopharmacol. Biol. Psychiatry 2014, 48:86-91.
30. Pan W., Banks W.A., Fasold M.B., Bluth J., Kastin A.J. Transport of brain-derived neurotrophic factor across the blood-brain barrier. Neuropharmacology 1998, 37:1553-1561.
31. Papakostas G.I., Culpepper L., Fayyad R.S., Musgnung J., Guico-Pabia C.J. Efficacy of desvenlafaxine 50mg compared with placebo in patients with moderate or severe major depressive disorder: a pooled analysis of six randomized, double-blind, placebo-controlled studies. Int. Clin. Psychopharmacol. 2013, 28:312-321.
32. Papakostas G.I., Thase M.E., Fava M., Nelson J.C., Shelton R.C. Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents. Biol. Psychiatry 2007, 62:1217-1227.
33. Piccinni A., Marazziti D., Catena M., Domenici L., Del Debbio A., Bianchi C., Mannari C., Martini C., Da Pozzo E., Schiavi E., Mariotti A., Roncaglia I., Palla A., Consoli G., Giovannini L., Massimetti G., Dell'Osso L. Plasma and serum brain-derived neurotrophic factor (BDNF) in depressed patients during 1 year of antidepressant treatments. J. Affect. Disord. 2008, 105:279-283.
34. Schatzberg A.F. Safety and tolerability of antidepressants: weighing the impact on treatment decisions. J. Clin. Psychiatry 2007, 68:26-34.
35. Sen S., Duman R., Sanacora G. Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications. Biol. Psychiatry 2008, 64:527-532.
36. Septien-Velez L., Pitrosky B., Padmanabhan S.K., Germain J.M., Tourian K.A. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatmentof major depressive disorder. Int. Clin. Psychopharmacol. 2007, 22:338-347.
37. Shimizu E., Hashimoto K., Okamura N., Koike K., Komatsu N., Kumakiri C., Nakazato M., Watanabe H., Shinoda N., Okada S., Iyo M. Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants. Biol. Psychiatry 2003, 54:70-75.
38. Shirayama Y., Chen A.C., Nakagawa S., Russell D.S., Duman R.S. Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression. J. Neurosci. 2002, 22:3251-3261.
39. Siuciak J.A., Lewis D.R., Wiegand S.J., Lindsay R.M. Antidepressant-like effect of brain-derived neurotrophic factor (BDNF). Pharmacol. Biochem. Behav. 1997, 56:131-137.
40. Tourian K.A., Padmanabhan S.K., Groark J., Brisard C., Farrington D. Desvenlafaxine 50 and 100mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies. Clin. Ther. 2009, 31:1405-1423.
41. Wolkowitz O.M., Wolf J., Shelly W., Rosser R., Burke H.M., Lerner G.K., Reus V.I., Nelson J.C., Epel E.S., Mellon S.H. Serum BDNF levels before treatment predicts SSRI response in depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 2011, 35:1623-1630.
42. Yoshimura R., Mitoma M., Sugita A., Hori H., Okamoto T., Umene W., Ueda N., Nakamura J. Effects of paroxetine or milnacipran on serum brain-derived neurotrophic factor in depressed patients. Prog. Neuropsychopharmacol. Biol. Psychiatry 2007, 31:1034-1037.
43. Ziegenhorn A.A., Schulte-Hebruggen O., Danker-Hopfe H., Malbranc M., Hartung H-D., Anders D. Serum neurotrophins-a study on the time course and influencing factors in a large old sample. Neurobiol. Aging 2007, 28:1436-1445.